Conexeu Sciences Inc. 8-K filed 2026-09-10

Conexeu Sciences Inc. filed an 8-K on 2026-09-10 under Item 3.02, Unregistered Sales of Equity Securities. The company reports that from June 18, 2026 through September 4, 2026 it issued an aggregate of 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants under various agreements and through the exercise of outstanding warrants. The company states this total exceeded 5% of its issued and outstanding common stock since its last periodic report, which is what triggered the disclosure. The largest single item is dated September 4, 2026, when the company issued 762,608 shares to one individual and three entities on exercise of warrants under its warrant exercise incentive program, at an exercise price of US$2.30 per share, for gross proceeds of $1,753,998.40. The company says it intends to use the proceeds for working capital and general corporate purposes. The rest of the disclosed issuances are share grants to consultants, two directors and a marketing counterparty at deemed prices that vary widely across a few weeks: $2.30, $7.07, $7.175, $7.79, $8.89, $9.34 and $13.96 per share. All of the shares described are restricted securities under Rule 144(a)(3), placed under Regulation D Rule 506(b), Section 4(a)(2) or Regulation S Rule 903(b) rather than registered. For an analyst or journalist, the readable story is dilution and how it is being paid for. Cash came in from one warrant exercise event, while a series of smaller issuances settled consulting, board and marketing obligations in stock instead of cash. Conexeu is a Nevada-incorporated operating company listed on Nasdaq under CNXU, classified under SIC 3842, orthopedic, prosthetic and surgical appliances and supplies, with an address at 50 West Liberty Street, Suite 880, Reno, NV, and it is flagged as an emerging growth company. The available text is an excerpt that cuts off mid-sentence in the July 23, 2026 marketing agreement item, so any issuances before that date are not shown here. Total shares outstanding, the names of the recipients and the terms of the 202,500 warrants are not in the excerpt.